{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Platelet count decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Anemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Diarrhea"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"White blood cell decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Activated partial thromboplastin time prolonged"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Alkaline phosphatase increased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Lymphocyte count decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Neutrophil count decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Sinus bradycardia"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"Adverse event data will be described and graded per the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 guidelines. The maximum grade for each type of toxicity will be recorded for each patient, and frequency tables will be reviewed to determine toxicity patterns, especially for grade 3 or above adverse events. To assess tolerability, will also capture the proportion of patients who go off treatment due to adverse events.","groups":[{"description":"Beginning within 7 days of the first administration of standard alemtuzumab, patients receive letermovir PO (or IV over 1 hour if patient is unable to take PO for an extended period of time) daily on days 1-28. Cycles repeat every 28 days for up to 3 months after the last dose of alemtuzumab in the absence of unacceptable toxicity.\n\nLetermovir: Given PO","id":"OG000","title":"Treatment (Letermovir)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 30 days post treatment, an average of 5 months","title":"Number of Participants With Adverse Events Grade 3 or Above","type":"SECONDARY","unitOfMeasure":"participants"}